Table 1.
Patient characteristics at baseline and pulmonary exacerbation onset.
| N = 28 | |
|---|---|
| Female: Male | 11:17 |
| Age in years, median (range) | 14 (8–18) |
| Genotype, N (%) | |
| F508del/F508del | 17 (61%) |
| F508del/other | 9 (32%) |
| Other/other or missing | 2 (7%) |
| Baseline FEV1% (highest predicted in prior 6 months), median (range) n = 27a | 96 (77–131) |
| FEV1% predicted at Visit 1, median (range) | 86 (64–122) |
| Change in FEV % predicted from baseline to visit 1, median (range) n = 27 | −10 (−45, 4) |
| Visit 1 PES total score, median (range) n = 27b | 6 (5–16) |
| CF respiratory culture results at visit 1 | |
| No CF pathogens detected | 4 (14%) |
| Methicillin sensitive Staphylococcus aureus | 13 (46%) |
| Methicillin Resistant Staphylococcus aureus | 5 (18%) |
| Pseudomonas aeruginosa | 8 (29%) |
| Stenotrophomonas maltophilia | 5 (18%) |
| Aspergillus | 3 (11%) |
| Haemophilus influenzae | 2 (7%) |
| Achromobacter xylosoxidans | 1 (4%) |
| Other | 3 (11%) |
| Positive Viral PCR at visit 1 | 11 (39%) |
| Antibiotic class prescribed | |
| Sulfa | 12 (43%) |
| Penicillin | 9 (32%) |
| Fluroquinolone | 5 (18%) |
| Cephalosporin | 1 (3.5%) |
| Oxazolidinone | 1 (3.5%) |
| Days between visits, median (range) | 18 (14–21) |
a
One subject did not have an FEV1 recorded in the prior six months.
b
One subject did not have a documented PES.